INSUBCONTINENT EXCLUSIVE:
NEW DELHI: In a major relief for rare disease patients, the government said on Friday it has approved the marketing of four drugs
manufactured by Indian pharmaceutical firms that are drastically cheaper than their imported versions.For example, while the annual cost of
the imported Nitisinonecapsule that is used in the treatment of Tyrosinemia Type 1 comes to Rs 2.2 crore, the domestically manufactured
capsules will now be available for just Rs 2.5 lakh.Tyrosinemia Type 1 is a rare disease that affects one in a lakh population.Similarly,
the domestically manufactured capsules will now be available for just Rs 3-6 lakh per annum.While the annual cost of the imported Nitisinone
capsule used in the treatment of Tyrosinemia Type 1 comes to Rs 2.2 crore, the domestically manufactured capsules will now be available for
it being manufactured indigenously it will be available Rs 2.2 lakh.The cost of the imported Cannabidiol (oral solution) used in treatment
of Dravet-Lennox Gastaut Syndrome comes to Rs 7-34 lakh per annum but with it being manufactured indigenously it will be available for Rs
1-5 lakh per annum, officials said.The commercial supply of Hydroxyurea Syrup used in the treatment of sickle cell anemia is likely to begin
by March 2024 and the tentative price would be Rs 405 per bottle
The cost of this oral suspension is $840 (Rs 70,000) per 100 ml
drugs used in treatment of the rare diseases, also referred to as the orphan drugs, started in July 2022 and discussions were held with
academia, pharma industries, organisations, CDSCO, Department of Pharmaceuticals after which 13 rare diseases were prioritised along with
After which interactions were held with drug manufacturers and the Drugs Controller General of India after which these drugs were approved
